Researcher:
Şenbabaoğlu, Fatih

Profile Picture
ORCID

Job Title

Master Student

First Name

Fatih

Last Name

Şenbabaoğlu

Name

Name Variants

Şenbabaoğlu, Fatih

Email Address

Birth Date

Filters

2010 - 20166

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.2fb9388f-5d84-4793-ae68-bc456d443ec1

Search Results

Now showing 1 - 6 of 6
  • Placeholder
    PublicationMetadata only
    Experimental analysis of boring process on automotive engine cylinders
    (Springer, 2010) Özkeser, Salih O.; N/A; Department of Mechanical Engineering; Şenbabaoğlu, Fatih; Lazoğlu, İsmail; Master Student; Faculty Member; Department of Mechanical Engineering; Graduate School of Sciences and Engineering; College of Engineering; N/A; 179391
    In this article, mechanics of boring process on cast iron automotive engine cylinders is explored experimentally. In order to shorten the boring cycle time and to improve quality of the cylinder holes, effects of various cutting conditions as spindle speed, feedrate, inserts, and coatings are investigated. Real-time cutting forces are measured with dynamometer during the process. Surface roughness on the engine cylinders, flank, and crater tool wears are measured and compared in various cutting conditions. It is concluded that by selecting proper cutting conditions, cutting forces can be controlled below a threshold value, cycle time can be shortened, tool life and part quality can be increased; therefore, the cost of automotive engine boring process can be reduced significantly.
  • Placeholder
    PublicationMetadata only
    Assessing the function of chromatin modifying enzymes in medulloblastoma
    (Oxford Univ Press Inc, 2016) Oppermann, Udo; N/A; N/A; N/A; Lokumcu, Tolga; Şenbabaoğlu, Fatih; Önder, Tuğba Bağcı; Master Student; Master Student; Faculty Member; Graduate School of Sciences and Engineering; Graduate School of Health Sciences; School of Medicine; N/A; N/A; 184359
    N/A
  • Placeholder
    PublicationMetadata only
    Examining the role of chromatin modifying enzymes in medulloblastoma by utilizing a chemical library
    (Elsevier, 2016) Oppermann, U.; N/A; N/A; N/A; Lokumcu, Tolga; Şenbabaoğlu, Fatih; Önder, Tuğba Bağcı; Master Student; Master Student; Faculty Member; Graduate School of Sciences and Engineering; Graduate School of Sciences and Engineering; School of Medicine; N/A; N/A; 184359
    N/A
  • Placeholder
    PublicationMetadata only
    Pharmacologic inhibition of c-jun n-terminal kinase (JNK) signaling pathway inhibits proliferation, blocks cell cycle progression and induces apoptosis of human granulosa cell tumor
    (Lippincott Williams and Wilkins (LWW), 2013) Taskiran, C.; Ata, B.; Arvas, M.; Urman, Cumhur Bülent; Öktem, Özgür; Müftüoğlu, Meltem; Şenbabaoğlu, Fatih; Faculty Member; Faculty Member; Faculty Member; Master Student; School of Medicine; School of Medicine; School of Medicine; Graduate School of Sciences and Engineering; 12147; 102627; 105916; N/A
    N/A
  • Placeholder
    PublicationMetadata only
    Mitoxantrone as a TRAIL-sensitizing agent for glioblastoma multiforme
    (Elsevier, 2016) Ayhan, Ceyda Açılan; N/A; N/A; N/A; Department of Molecular Biology and Genetics; N/A; N/A; Şenbabaoğlu, Fatih; Cingöz, Ahmet; Kaya, Ezgi; Kazancıoğlu, Selena; Lack, Nathan Alan; Önder, Tuğba Bağcı; Master Student; Researcher; PhD Student; Undergraduate Student; Faculty Member; Faculty Member; Department of Molecular Biology and Genetics; Graduate School of Sciences and Engineering; Graduate School of Health Sciences; Graduate School of Health Sciences; College of Sciences; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; 120842; 184359
    Background: Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) has tremendous promise in treating various forms of cancers. However, many cancer cells exhibit or develop resistance to TRAIL. Interestingly, many studies have identified several secondary agents that can overcome TRAIL resistance. To expand on these studies, we conducted an extensive drug-re-profiling screen to identify FDA-approved compounds that can be used clinically as TRAIL-sensitizing agents in a very malignant type of brain cancer, glioblastoma multiforme (GBM). Material and Methods: GBM cell lines U87MG, U373 and non-malignant cell lines BJ fibroblasts and Normal Human Astrocytes were used in in vitro experiments. 1,200 FDA approved drugs containing library was screened as single agents (5 uM) and/or TRAIL (25 ng/ml) in U87MG and U87MGR50. Cell viability was detected by an ATP-based assay after 24−48 hours. Chosen lead, Mitoxantrone was further studied by cell viability assays, proliferation by live cell imaging, apoptotic gene expression levels by qRT-PCR and death receptor and apoptotic protein expression levels by Western Blot. Results: Using selected isogenic GBM cell pairs with differential levels of TRAIL sensitivity, we revealed 26 TRAIL-sensitizing compounds, 13 of which were effective as single agents. Cardiac glycosides constituted a large group of TRAIL-sensitizing compounds, and they were also effective on GBM cells as single agents. We then explored a second class of TRAIL-sensitizing drugs, which were enhancers of TRAIL response without any effect on their own. One such drug, Mitoxantrone, a DNA-damaging agent, did not cause toxicity to non-malignant cells at the doses that synergized with TRAIL on tumor cells. We investigated the downstream changes in apoptosis pathway components upon Mitoxantrone treatment, and observed that Death Receptors (DR4 and DR5) expression was upregulated, and pro-apoptotic and anti-apoptotic gene expression patterns were altered in favor of apoptosis. Conclusions: Together, our results suggest that combination of Mitoxantrone and TRAIL can be a promising therapeutic approach for GBM patients.
  • Placeholder
    PublicationMetadata only
    Titanium machining with new plasma boronized cutting tools
    (Elsevier, 2010) Baştürk, Süleyman; Erten, M.; Gülmez, Turgut; Department of Mechanical Engineering; Şenbabaoğlu, Fatih; İslam, Coşkun; Lazoğlu, İsmail; Master Student; Master Student; Faculty Member; Department of Mechanical Engineering; Graduate School of Sciences and Engineering; Graduate School of Sciences and Engineering; College of Engineering; N/A; N/A; 179391
    Titanium is a commonly used material in various critical applications such as aerospace and biomedical applications. In this article, for the first time in the literature, development and implementation of a novel plasma boronizing process on Tungsten Carbide (WC) cutting tools is introduced. Plasma boronizing on WC tools is performed with gas combination of 10% BF3, 40% Argon and 50% H-2 at different temperatures and durations. Performance enhancements of plasma boronized WC tools on Titanium (Ti-6Al-4V) machining are investigated under various cutting conditions. It is found that new plasma boronizing of WC is a very cost effective solution for significantly increasing tool life in Titanium machining. (C) 2010 CIRP.